Business
Emergent BioSolutions Secures over $60 Million in New Contract Award with the U.S. Government and New Orders with an International Government Partner for Smallpox Medical Countermeasures
GAITHERSBURG, Md., March 25, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has secured a contract award valued at approximately $54 million USD to deliver CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) to the Administration for Strategic Preparedness and Response (ASPR), part of the U. S. Department of Health and Human Services (HHS), for smallpox preparedness. ASPR exercised an option from its existing 10-year contract (75A50119C00037) for a
About this update from Emergent Biosolutions Inc.
[{"type":"image","alt":"Emergent BioSolutions","displaySize":"","headline":null,"caption":"Emergent BioSolutions","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":36,"url":"https://media.zenfs.com/en/globenewswire.com/ac51a05701131dc10043a5f2860c099d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ZhYU3Wj_ScFJfNSBcZGgMw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTUw/https://media.zenfs.com/en/globenewswire.com/ac51a05701131dc10043a5f2860c099d","width":300,"height":36}},"lazy":false},{"type":"text","content":"GAITHERSBURG, Md., March 25, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has secured a contract award valued at approximately $54 million USD to deliver CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) to the Administration for Strategic Preparedness and Response (ASPR), part of the U. S. Department of Health and Human Services (HHS), for smallpox preparedness. ASPR exercised an option from its existing 10-year contract (75A50119C00037) for additional doses of VIGIV, a treatment for complications due to smallpox vaccination.","length":584,"tagName":"p"},{"type":"text","content":"In addition, Emergent has secured new incremental orders with an international government partner valued at $6.6 million USD. This represents product orders for ACAM2000® (Smallpox (Vaccinia) Vaccine, Live) within Emergent’s medical countermeasures portfolio and will support the partner’s smallpox biodefense strategy. These orders stem from a recurring international customer and demonstrate the importance of threat preparedness around the world.","length":449,"tagName":"p"},{"type":"text","content":"“We are pleased to support both the U.S. government and a longstanding international partner with critical smallpox medical countermeasures that directly align with their national security and public health preparedness efforts,” said Paul Williams, senior vice president, head of products business, global government & public affairs at Emergent. “Our strong track record of developing, manufacturing and supplying biodefense products to international governments reinforces the strength of our partnerships, particularly in light of the growing risk of biological threats globally.”","length":588,"tagName":"p"},{"type":"text","content":"This announcement follows Emergent’s recent execution of ...